Calcyon Forms a Novel Ternary Complex with Dopamine D1 Receptor through PSD-95 Protein and Plays a Role in Dopamine Receptor Internalization*

Background: Calcyon has been associated with various dopamine D1 receptor signalings despite no direct interaction between them. Results: Calcyon forms a novel ternary complex with D1DR through PSD-95. Conclusion: Calcyon, by forming a ternary complex, regulates D1DR internalization in a phosphorylation-dependent manner. Significance: Regulation of dopaminergic signaling by calcyon·PSD-95·D1DR complex may represent a novel target for related neuropsychiatric disorders. Calcyon, once known for interacting directly with the dopamine D1 receptor (D1DR), is implicated in various neuropsychiatric disorders including schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder. Although its direct interaction with D1DR has been shown to be misinterpreted, it still plays important roles in D1DR signaling. Here, we found that calcyon interacts with the PSD-95 and subsequently forms a ternary complex with D1DR through PSD-95. Calcyon is phosphorylated on Ser-169 by the PKC activator phorbol 12-myristate 13-acetate or by the D1DR agonist SKF-81297, and its phosphorylation increases its association with PSD-95 and recruitment to the cell surface. Interestingly, the internalization of D1DR at the cell surface was enhanced by phorbol 12-myristate 13-acetate and SKF-81297 in the presence of calcyon, but not in the presence of its S169A phospho-deficient mutant, suggesting that the phosphorylation of calcyon and the internalization of the surface D1DR are tightly correlated. Our results suggest that calcyon regulates D1DR trafficking by forming a ternary complex with D1DR through PSD-95 and thus possibly linking glutamatergic and dopamine receptor signalings. This also raises the possibility that a novel ternary complex could represent a potential therapeutic target for the modulation of related neuropsychiatric disorders.

Calcyon, once known for interacting directly with the dopamine D 1 receptor (D 1 DR), is implicated in various neuropsychiatric disorders including schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder. Although its direct interaction with D 1 DR has been shown to be misinterpreted, it still plays important roles in D 1 DR signaling. Here, we found that calcyon interacts with the PSD-95 and subsequently forms a ternary complex with D 1 DR through PSD-95. Calcyon is phosphorylated on Ser-169 by the PKC activator phorbol 12-myristate 13-acetate or by the D 1 DR agonist SKF-81297, and its phosphorylation increases its association with PSD-95 and recruitment to the cell surface. Interestingly, the internalization of D 1 DR at the cell surface was enhanced by phorbol 12-myristate 13-acetate and SKF-81297 in the presence of calcyon, but not in the presence of its S169A phospho-deficient mutant, suggesting that the phosphorylation of calcyon and the internalization of the surface D 1 DR are tightly correlated. Our results suggest that calcyon regulates D 1 DR trafficking by forming a ternary complex with D 1 DR through PSD-95 and thus possibly linking glutamatergic and dopamine receptor signalings. This also raises the possibility that a novel ternary complex could represent a potential therapeutic target for the modulation of related neuropsychiatric disorders.
As a brain-specific protein, calcyon is mainly localized in the intracellular endosomal vesicles of dendritic spines in D 1 DR 3expressing pyramidal cells in the prefrontal cortex and hippocampus and dorsal striatum region (1,2). Initially, calcyon had been reported as a D 1 DR-interacting protein (DRIP), but later studies revealed that there was no direct interaction between calcyon and D 1 DR (3). Recent studies, however, have introduced calcyon as a candidate gene for D 1 DR-related neurophysiological disorders. Calcyon levels were elevated in schizophrenia patients (4,5), whereas calcyon transgenic mice showed reduced anxiety and an impaired working memory (6,7). Calcyon was up-regulated in the rodent model of attention deficit hyperactivity disorder (8), and its gene variations are known to be associated with cocaine dependence (9). In addition, calcyon is known to potentiate cross-talk between G␣ slinked D 1 DR and heterologous G q/11 -coupled receptors. When primed with agonists to G q/11 -coupled receptors, calcyon induces D 1 DR to stimulate intracellular Ca 2ϩ release (2,10). Therefore, all of the above results suggest a possible functional interaction between calcyon and D 1 DR despite no direct interaction between them. Indeed, a recent study suggested that calcyon-containing vesicles might transport D 1 DR by associat-ing calcyon with D 1 DR through their assembly to clathrin (11). However, as a single transmembrane protein, it is not clear how calcyon can regulate the internalization of D 1 DR from the plasma membrane to endocytic vesicles.
PSD-95 is prominently expressed in postsynaptic densities (PSDs) and is a prototypical scaffolding protein with multiple protein interaction domains: NH 2 -terminus, Discs large/zona occludens-1 (PDZ), SH3 (Src homology 3), and guanylate kinase-like domains (12). It forms the backbone of the postsynaptic protein complex that organizes receptors and signal transduction molecules, enabling the functional effects of the receptors at PSDs. PSD-95 is known to regulate D 1 DR signaling and the formation of the D 1 DR-associated protein⅐protein complex (13,14). The NH 2 terminus of PSD-95 interacts with the carboxyl-terminal tail of D 1 DR and facilitates constitutive D 1 DR internalization as well as internalization of the NMDA receptor, which complexes with D 1 DR, thus linking dopamine signaling and glutamatergic signaling (15).
Here, we show that calcyon interacts with PSD-95. This interaction formed a ternary protein complex containing calcyon⅐PSD-95 and D 1 DR in the dendritic spines of hippocampal neurons. Furthermore, we found that calcyon was phosphorylated on the Ser-169 residue through a PKC-dependent pathway. Phosphorylation of calcyon strongly enhanced its interaction with PSD-95, increased its surface localization, and consequently induced the internalization of the surface D 1 DR.

EXPERIMENTAL PROCEDURES
Constructs-To construct expression vectors for calcyon, rat full-length calcyon cDNA (accession number: AF303658) was extracted by PCR from rat brain cDNA library and inserted into target vectors (EGFP-C1, pCDNA3-HA, and C-terminal FLAG-tagged pFLAG-CMV (Sigma). Serine phosphorylation site of calcyon (S169A) was generated by site-directed point mutations using the QuikChange site-directed mutagenesis kit (Stratagene. Austin, TX). Full-length rat PSD-95 (accession number: P31016) was amplified by PCR and subcloned into pCDNA3-HA and EGFP-N1 vectors (Invitrogen). The HA-D 1 DR was kindly provided by Dr. Wei-Dong Yao (Harvard University), and all DNA constructs were verified by DNA sequencing. These expression vectors were transfected into HEK293T, SH-SY5Y cells, and neurons for Western blot and imaging analysis.
To identify the endogenous ternary complex of calcyon⅐PSD-95⅐D 1 DR, cultured hippocampal neuron lysates (days in vitro 16) were prepared after treatment of SKF-81297 (10 M) for 15 min and harvested with modified RIPA buffer. They were then clarified by centrifugation at 15,000 ϫ g for 30 min. Protein concentrations were measured using a BCA assay (Pierce).

Calcyon⅐PSD-95⅐D 1 DR Complex in Dopamine Receptor Trafficking
In Vitro Phosphorylation Assay-The 156 -206-a.a domains of calcyon (P-WT) and S169A mutant (P-SA) were cloned into pDEST15 vector using the Gateway cloning system and transformed to BL-21. The Escherichia coli was sonicated with lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, 20 mM Tris, 150 Mm NaCl, 1 mM MgCl 2 , 1 mM EGTA, PH 7.2, 0.1 mM PMSF). The phosphorylation of wild type (P-WT) and phospho-mutant S169A (P-SA) was performed using glutathione-Sepharose 4B resin (GE Healthcare). For the in vitro phosphorylation assay, 25 g of purified GST-P-WT and GST-P-SA were incubated with 20 ng of PKC-catalytic subunit (Millipore, Billerica, MA) in PKC assay dilution buffer II with 2 mM Mg 2ϩ -ATP containing phosphatase inhibitor mixture III (Sigma) at 30°C for 40 min. The reaction was stopped by adding 10 mM EDTA and centrifuged at 1000 ϫ g for 1 min, and the supernatant was removed. 2ϫ SDS-Laemmli buffer was added without washing followed by SDS-PAGE. P-WT phosphorylation was detected by immunoblotting with phospho-serine antibody (Acris Antibodies GmbH).
cAMP Enzyme Immunoassay-HEK293T cells were transiently transfected with FLAG-calcyon, PSD-95-EGFP, and HA-D 1 DR using Lipofectamine 2000 (Invitrogen) and grown for 27 h in complete DMEM medium and then serum-starved for 16 h before SKF-81297 treatment. The cells were stimulated by 10 M SKF-81297 for 30 min, and cAMP accumulation was measured with a cAMP direct immunoassay kit (Abcam). In brief, DMEM was removed from the plate, and cells were washed with warmed 1ϫ Dulbecco's PBS briefly and incubated with 0.1 M HCl at room temperature for 20 min. Cells were dissociated by pipetting up and down, neutralizing buffer and acetylation reagent mixture were added to the cell lysates (Ͼ1 g/l concentration), and reaction mixtures were incubated at room temperature for 10 min. Each acetylated sample and standards were transferred to a protein G-coated white 96-well plate. Rabbit anti-cAMP polyclonal antibody was added to standard, and samples and reaction mixtures were incubated for 1 h at room temperature, reincubated with cAMP-HRP for 1 h, washed, and developed with the HRP developer for 1 h. The reaction was stopped by adding 1 M HCl and read the plate at an optical density of 450 nm.
Cell Culture, Immunocytochemistry, and Image Acquisition-HEK293T and SH-SY5Y cells were cultured at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Transfection was carried out using Lipofectamine 2000 (Invitrogen), and cells were observed after 24 -36 h. The confocal images were acquired with an Olympus FV 1000 using a sequential scan tool mounted on an Olympus IX-81 microscope fitted with a 100ϫ/1.4 NA objective lens driven by Olympus FluoView software. For immunocytochemistry, cells were fixed in 4% formaldehyde with 4% sucrose in PBS for 15 min, permeabilized for 5 min in 0.25% Triton X-100, PBS, and blocked for 30 min in 10% BSA, PBS at 37°C. The cells were incubated with primary antibodies in 3% BSA, PBS for 2 h at 37°C or overnight at 4°C, washed in PBS, and incubated with secondary antibodies in 3% BSA, PBS for 45 min at 37°C. For colocalization experiments with calcyon, PSD-95 and D 1 DR, primary cultured neurons were permeabilized with 0.25% Tri-ton X-100 for 5 min at room temperature before primary antibodies. Analysis and quantification of data were performed with MetaMorph software (Molecular Devices, Sunnyvale, CA) and SigmaPlot 8.0 (Systat Software, Point Richmond, CA), and data are presented as means Ϯ S.E.
Neuron Culture and Transfection-Experiments were performed in accordance with guidelines set forth by the Seoul National University Council Directive for the proper care and use of laboratory animals. Hippocampal neurons derived from E-18 primary rats were prepared as described (17). Briefly, hippocampi were dissected, dissociated with papain, and triturated with a polished half-bore Pasteur pipette. The cells (2.5 ϫ 10 5 ) in minimum Eagle's medium supplemented with 0.6% glucose, 1 mM pyruvate, 2 mM L-glutamine, 10% fetal bovine serum, and antibiotics were plated on poly-D-lysine-coated glass coverslips in a 60-mm Petri dish. Four hours after plating, the medium was replaced with basal media Eagle's (Invitrogen) supplemented with 2% B-27, 10 mM HEPES, and 0.5 mM pyruvate or Neurobasal medium (Invitrogen) supplemented with 2% B-27, 0.5 mM L-glutamine. 4 M 1-␤-D-cytosine-arabinofuranoside (Ara-C, Sigma) was added as needed. Neurons were transfected using the calcium phosphate method (18).
Surface Biotinylation-After 36 h of transfection, biotinylation of cell surface proteins was performed using the cell surface protein isolation kit (Thermo scientific) according to the manufacturer's instructions. Briefly, HEK293 cells grown on 100-mm plates were washed once with ice-cold PBS and incubated with 0.25 mg/ml EZ-Link Sulfo-NHS-SS-Biotin in PBS for 30 min at 4°C. The cells were rinsed in quenching solution with Tris-buffered saline to remove free biotin reagents and lysed in lysis buffer. After centrifugation, supernatants were incubated with 50 l of 50% slurry of immobilized NeutrAvidin for 3 h at 4°C. Reaction complexes were washed three times with wash buffer, and then biotinylated proteins were eluted by incubating at 37°C for 15 min in SDS sample buffer followed by immunoblotting with an anti-HA antibody (1:1000) to detect D 1 DR and anti-calcyon (1:1,000) antibodies.

RESULTS AND DISCUSSION
A previous study showed that calcyon localizes to the dendritic spines of D 1 receptor-expressing pyramidal cells in the prefrontal cortex (2). PSD-95 is a prominent scaffolding protein with multiple protein interaction domains in the dendritic spine (19,20). Because the subcellular fractionation data in this study showed that calcyon and PSD-95 protein existed in the PSD and had similar expression patterns during the develop-
To test this possibility, an immunoprecipitation analysis was performed with adult rat whole brain lysates. Fig. 1 shows that calcyon and PSD-95 coprecipitated, suggesting that they interact with each other endogenously (Fig. 1A). When HEK293T cells were cotransfected with FLAG-calcyon, EGFP-C 1 empty vector, clathrin light chain (Lca)-EGFP, and PSD-95-EGFP, calcyon coprecipitated with Lca (lane 2) and PSD-95 (lane 3) but not with the EGFP empty vector (Fig. 1B). This interaction was further confirmed by BiFC assay using the improved yellow fluorescence protein, Venus, which allows for direct visualization of protein interactions at the subcellular sites of their interactions in living cells (21)(22)(23). Fluorescence complementation was only observed in a group of cells that coexpressed fragments of Venus (VN173 or VC155) conjugated to the C terminus of calcyon and to the N terminus of PSD-95 (Fig. 1C). No complementation was detected when fragments of Venus (VN173 or VC155) were fused to the N terminus of calcyon or the C terminus of PSD-95 (supplemental Fig. 2A).
We further investigated which domain of PSD-95 binds to calcyon. A series of GST pulldown assays was done with various domain mutants of PSD-95 and calcyon (Fig. 2, A and B). Calcyon was found to interact with the full-length PSD-95, the PDZ1-3 domain, and the PDZ1 domain, but not with the N-terminal region, PDZ2, PDZ3, or SH3 domain (Fig. 2C). In addition, the full-length PSD-95 and PDZ1 domain of PSD-95 interacted with the C terminus (a.a. 109 -226) and C-terminal end (a.a. 175-226) of calcyon, but not with the extracellular region or GST only (Fig. 2D). These results suggest that the PDZ1 domain of PSD-95 is responsible for its binding to the C-terminal regions (a.a. 175-226) of calcyon. Although we did not find any consensus binding motif for the class I PDZ domain (X(S/T)X(V/L/I)-COOH) in the C-terminal regions of calcyon, using the PDZ domain-ligand interaction network (PDZNet) and position weight matrices, which contain the experimental data of the PDZ domain-ligand interaction of human PDZ domains (21), we could identify the three putative PDZ binding motifs in the C-terminal regions of calcyon (supplemental Fig. 2C). We thus divided the C-terminal regions (a.a. 175-226) into two regions (a. a. 175-200 and a.a. 201-226, respectively) that contained the putative PDZ binding motif(s) and performed a GST pulldown assay. We found that a.a. 201-226 of calcyon strongly bound to PSD-95, whereas a.a. 175-200 did not. This was further supported by the BiFC results in which a group of cells that coexpressed fragments of PSD-95-VN173 or VN173-PSD-95 with the calcyon-VC155 (a.a. 201-226) only showed fluorescent complementation (Fig. 2E and supplemental Fig. 2B). Because both C-terminal fragments contain the AXXV motif, these results indicate that AXXV motif does not seem to be involved in PSD-95 binding. To test whether the last four-amino acid sequence (QSPK) of calcyon is the PSD-95 binding motif, we introduced S224A point mutation in the Ser residue of the sequence because Ser/Thr at the Ϫ2 position is the most conserved residue among various PDZ binding motifs (21). We found that the S224A mutant failed to bind PSD-95, whereas the wild type strongly binds to PSD-95 (Fig. 2F).
Interaction of calcyon with PSD-95 was further confirmed by immunocytochemistry. Neurons were doubly stained with calcyon and PSD-95 antibodies. Although calcyon was found to be present throughout the cytosol, it partially colocalized with PSD-95 in the dendritic spines (supplemental Fig. 3A). When exogenously expressed, calcyon also was found in the punctate structures, which were partially colocalized with the endosomal marker, EEA1, in the dendritic spines (supplemental Fig. 3B). Consistent with endogenous staining, exogenously expressed calcyon also exhibited partial colocalization with PSD-95 (supplemental Fig. 3E). We also found that calcyon was partially colocalized with various early endosome markers; early endosome antigen 1 protein (EEA1), double FYVE domain from the hepatocyte-growth-factor-regulated tyrosine kinase substrate (2XFYVE-Hrs) or transferrin-conjugated Texas Red in COS-7 cells (supplemental Fig. 4).
The N terminus of PSD-95 is known to interact with the C terminus of D 1 DR (13). Although a direct interaction between calcyon and D 1 DR turned out to be misinterpreted because our results indicated that calcyon and PSD-95 associate with each other, there is a possibility that calcyon and D 1 DR interact indirectly through PSD-95 as a mediator. To test this possibility, we first incubated purified GST-calcyon or GST-only with HEK293T cell lysates that expressed HA-D 1 DR and PSD-95-EGFP and immunoprecipitated with GST antibody followed by immunoblotting with HA-antibody. We found that HA-D 1 DR was coimmunoprecipitated with GST-calcyon (Fig. 3A). Second, HEK293T cells were transfected with various combinations of HA-D 1 DR, PSD-95-GFP, and FLAG-calcyon, and coimmunoprecipitation followed by immunoblotting with specific antibodies was carried out. PSD-95-GFP was coprecipitated with either FLAG-calcyon or HA-D 1 DR when doubly transfected. Interestingly, HA-D 1 DR and FLAG-calcyon only coprecipitated if PSD-95-GFP was triply cotransfected, strongly suggesting that PSD-95 acts as a linker between calcyon and D 1 DR (Fig. 3B). Finally, we confirmed that a calcyon⅐PSD-95⅐D 1 DR ternary complex exists endogenously in the brain by immunoprecipitation assay in cultured neurons after treatment with a D 1 DR-specific agonist, SKF-81297 for 15 min. Immunoblot analysis with antibodies against each protein showed that calcyon, PSD-95, and D 1 DR coprecipitated together (Fig. 3C). Immunocytochemistry also showed that the three proteins are colocalized in the dendritic spines, especially the spine heads ( Fig. 3D and supplemental Fig. 5).
The D 1 -like receptors activate cyclic AMP production and bidirectionally modulate protein kinase A (PKA) and DARPP-32 through G s/olf (24). Intriguingly, D 1 DR-stimulated Ca 2ϩ release was significantly attenuated by treatment with a PKC inhibitor in calcyon-expressing cells, and calcyon was found to be phosphorylated by purified PKC, although no detailed analysis has been done (2). We also found that calcyon was phosphorylated on the serine residue by the PKC activator PMA, and this phosphorylation was blocked by the PKC inhibitors GF109203X and rottlerin but not by the PKA inhibitor H-89 (Fig. 4A). We further investigated the specific phosphorylation sites of calcyon by PKC. Human calcyon is phosphorylated on Ser-154 and Ser-196 by PKA (2), whereas the rat calcyon has a putative PKC phosphorylation site on Ser-169 in the cytoplasmic domain (the NetPhosK 1.0 Server). HEK293T cells were transfected with an EGFP-tagged wild-type calcyon or S169A phospho-deficient mutant and incubated with PMA. Fig. 4B shows that the wild type, but not the S169A mutant, was rapidly phosphorylated on the serine residues by PMA, suggest- ing that Ser-169 is the major phosphorylation site of calcyon by PKC. This was further confirmed by an in vitro phosphorylation assay (Fig. 4C). We purified a.a 156 -187 from wild type (P-WT) and the phospho-deficient mutant S169A (P-SA) of calcyon and incubated them with the purified PKC catalytic subunit in the presence of ATP. Phosphorylation on the serine residues was observed in the P-WT but not in the P-SA, suggesting that calcyon is directly phosphorylated by PKC on Ser 169 (Fig. 4C).
We next tested whether the phosphorylation of calcyon modulates its interaction with PSD-95. HEK293T cells were transfected with FLAG-calcyon and incubated with 1 M PMA for 10 min. Then, the lysates were precipitated with purified GST-PSD-95 beads and immunoblotted with FLAG-antibodies. Fig. 4D shows that the interaction between calcyon and PSD-95 was dramatically increased by treatment with PMA. Interestingly, calcyon was also phosphorylated on the serine residues after SKF-81297 treatment, whereas the S169A mutant was not (Fig. 4E). Direct activation of PKC by PMA resulted in a maximum increase of calcyon phosphorylation only 5 min after treatment (Fig. 4B), whereas SKF-81279 treatment induced maximum calcyon phosphorylation 15 min after After preincubation, cells were treated with 1 M PMA, a PKC activator, for 10 min, harvested, and coimmunoprecipitated with anti-GFP antibody followed by immunoblotting with anti-phospho-serine antibody. Lower bar graphs: quantification from three independent experiments. Data are the mean Ϯ S.E. Asterisks indicate a significant change when compared with the group(s) indicated (one-way ANOVA; *, p Ͻ 0.05, **, p Ͻ 0.01). CTL, control. B, HEK293T cells expressing EGFP-calcyon (EGFP-Cal) or phospho-deficient mutant EGFP-calcyon (S169A) (EGFP-Cal (S169A)) were incubated with PMA for the indicated times and coimmunoprecipitated with anti-GFP antibody followed by immunoblotting with phospho-serine (P-Ser) antibody. C, purified GST-tagged wild type (P-WT) and phospho-deficient mutant S169A (P-SA) of calcyon were incubated with the PKC catalytic subunit in the presence of ATP. The phosphorylation was analyzed by SDS-PAGE and immunoblotting with phospho-serine antibody (left panel). Arrowheads indicate the PKC catalytic subunit and phosphorylated serine. Purified GST fusion proteins were identified using Coomassie Blue staining (right panel). D, HEK293T cells expressing FLAG-calcyon were incubated with 1 M PMA for 10 min, and lysates were coprecipitated with GST-PSD-95 beads and immunoblotted with anti-FLAG antibody. The amount of FLAG-calcyon pulled down with GST-PSD-95 increased more than 3-fold after treatment with PMA for 10 min. Statistical analysis was performed using Student's t test. **, p Ͻ 0.01. AU, arbitrary units. E, HA-D 1 DR⅐PSD-95-EGFP and FLAG-calcyon or FLAG-calcyon (S169A) were cotransfected into HEK293T cells. After treatment with SKF-81297 for the indicated times, cells were lysed and immunoprecipitated with anti-FLAG antibody followed by immunoblotting with phospho-serine antibody. Note that in the absence of HA-D 1 DR expression, SKF-81297 treatment failed to induce the phosphorylation of calcyon. Lower graph: quantification from three independent experiments. Asterisks indicate significant changes in the second group when compared with the first and the third group at matching time points. ANOVA and Tukey's HSD post hoc test; **, p Ͻ 0.01. F, HA-D1DR⅐PSD-95-EGFP and FLAG-calcyon or FLAG-calcyon (S169A) were cotransfected into HEK293T cells. After treatment of SKF-81297 for the indicated times, cells were lysed and immunoprecipitated with anti-GFP antibody followed by immunoblotting with anti-FLAG antibody. Phosphorylation of calcyon by SKF-81297 increased its interaction with PSD-95. Asterisk indicates significant changes in the second group when compared with the first group at matching time points. ANOVA and Tukey's HSD post hoc test; *, p Ͻ 0.05.

Calcyon⅐PSD-95⅐D 1 DR Complex in Dopamine Receptor
Trafficking treatment (Fig. 4E), suggesting that D 1 DR activation by SKF-81297 indirectly causes PKC activation during D 1 DR signal transduction. Consistently, SKF-81297 treatment significantly increased the interaction of PSD-95 with calcyon but not with the S169A mutant (Fig. 4F).
PSD-95 interacts with D 1 DR, promoting the internalization of the surface D 1 DR (13). Thus, we next investigated whether calcyon could regulate the internalization of the surface D 1 DR through the ternary complex with PSD-95. HEK293T cells were triply cotransfected with HA-D 1 DR, PSD-95-EGFP, and the FLAG-calcyon or FLAG-S169A mutant. The surface biotinylation assay showed that the surface level of D 1 DR rapidly decreased after treatment with SKF-81297 in the presence of calcyon. When compared with the D 1 DR only or D 1 DR with PSD-95 groups, when calcyon was cotransfected with D 1 DR and PSD-95, the slope of the decrease was much steeper (Fig.  5A). The phospho-deficient S169A mutant of calcyon failed to induce D 1 DR internalization after treatment with SKF-81297 (Fig. 5A).
To further test whether the decrease in the surface level of D 1 DR depends on the phosphorylation of calcyon, triply cotransfected HEK293T cells were incubated with 10 M SKF-81297, 1 M PMA, or 5 M GF109203X, and the surface levels of D 1 DR were measured. Fig. 5B shows that both PMA and SKF-81297 treatments induced significant decreases in the surface level of D 1 DR, whereas GF109203X treatment did not. Evidently, the S169A mutant did not induce any significant changes in the surface levels of D 1 DR after treatment with PMA, SKF-81297, or GF109203X (Fig. 5B). To test whether the formation of the ternary complex has an effect on D 1 DR-mediated signaling, HEK293T cells were transfected with various combinations of constructs, and after incubation with 10 M SKF-81297 for 30 min, cAMP levels were measured (Fig. 5C). We found that in the presence of calcyon, PSD-95, and D 1 DR, SKF-81297-stimulated cAMP production was significantly reduced when compared with D 1 DR only or PSD-95 with D 1 DR. The phospho-deficient mutant of calcyon (S169A) failed to affect cAMP production. Because the interaction between FIGURE 5. The phosphorylation of calcyon and the internalization of the surface D 1 DR are tightly correlated. A, HEK293T cells were transfected with various combinations of constructs as indicated. Cells were then exposed to 10 M SKF-81297 for the indicated times, and surface biotinylation experiments were performed as described under "Experimental Procedures." The surface levels of D 1 DR were gradually decreased after SKF-81297 treatments in cells coexpressing D 1 DR and PSD-95 or D 1 DR, PSD-95 and calcyon, although when the three proteins were coexpressed, the rate of decrease was much faster. The phospho-deficient mutant of calcyon (S169A) failed to induce D 1 DR internalization after treatment with SKF-81297. Lower graphs: quantification from five independent experiments (left graph). The surface intensity values of D 1 DR at the indicated times were normalized to the that at time 0 to emphasize the rate of internalization of surface D 1 DR after SKF-81297 treatment (right graph). Asterisks indicate significant changes in each group when compared with the HA-D 1 DR group at matching time points. ANOVA and Tukey's HSD post hoc test; *, p Ͻ 0.05, **, p Ͻ 0.01. B, HEK293T cells expressing the FLAG-calcyon (FLAG-Cal) or FLAG-calcyon (S169A) with HA-D1DR⅐PSD-95-EGFP were incubated with 10 M SKF-81297 or 1 M PMA for 30 min in the presence or absence of 5 M GF109203X (GFX). Surface biotinylation experiments were performed, and surface as well as total levels of D 1 DRs were measured by immunoblotting with anti-HA antibody. The intensity of surface biotinylated proteins was normalized to the total protein intensity. Lower graphs: quantification from three independent experiments. Asterisks indicate significant changes in the PMA-or SKF-81297-treated group when compared with the DMSO-treated group or GF109203X-treated group. Data represent the mean Ϯ S.E. ANOVA and Tukey's HSD post hoc test; *, p Ͻ 0.05, **, p Ͻ 0.01. C, HEK293T cells were transfected with the same constructs as in A. Cells were then exposed to 10 M SKF-81297 for 30 min, and cAMP direct immunoassays were performed as described under "Experimental Procedures." The SKF-81297-induced cAMP accumulation levels were significantly diminished in cells coexpressing D 1 DR, PSD-95, and calcyon when compared with D 1 DR or D 1 DR with PSD-95. The data are means Ϯ S.E. from at least three independent experiments. Asterisks indicate significant changes between linked groups. ANOVA and Tukey's HSD post hoc test; *, p Ͻ 0.05. calcyon and PSD-95 increased by the phosphorylation of calcyon, our results suggest that D 1 DR activation by SKF-81297 induces the PKC-mediated phosphorylation of calcyon, which promotes the formation of a ternary complex between calcyon and D 1 DR through PSD-95 and consequently induces the internalization of D 1 DR, thus inhibiting D 1 DR signaling.
Previously, calcyon and D 1 DR were thought to interact with each other, but later on, it was discovered there was no direct interaction between them (8). Growing evidence, however, indicates that calcyon has important roles in D 1 DR-mediated signaling pathways as well as in various D 1 DR-related neuropsychiatric disorders (4,5,(25)(26)(27). Therefore, it was widely assumed that calcyon could interact with D 1 DR either functionally or indirectly. D 1 DR is regulated by the glutamatergic scaffolding protein PSD-95 through direct interaction, which facilitates the constitutive internalization of D 1 DR as well as the internalization of the NMDA receptor that complexes with D 1 DR (15). In addition, D 1 DR interacts with NMDA receptor and balances NMDA receptor-mediated responses through both a PKA-dependent pathway and a Ca 2ϩ -dependent mechanism (28). Furthermore, recent studies revealed that calcyon is required for the NMDA activity-dependent internalization of AMPA receptor, which leads to long-term depression (29). All of these results imply that there could be many possible interactions involving D 1 DR, calcyon, and glutamate receptors. In the present study, we showed that calcyon forms a novel ternary complex with D 1 DR through PSD-95, thus linking calcyon to D 1 DR.
The PDZ homology domain is the most abundant protein interacting domain, and greater than 500 PDZ domains have been identified in eukaryotic cells so far (30). The PDZ1 domain of PSD-95 is known to interact with GluR6, the C terminus of the NMDA receptor NR2 subunits, and the C terminus of the Kir2.1 and Kv1.4 potassium channels (31)(32)(33)(34). There are no reports as to whether rat calcyon has the PDZ binding motif, but we found that the last four-amino acid sequence (QSPK) of calcyon mediates the interaction with the PDZ-1 domain of PSD-95 ( Fig. 2E and supplemental Fig. 2, B and C). Therefore, calcyon may compete with other proteins for binding to PSD-95, which subsequently affects the signaling pathways downstream to these proteins, although this requires further detailed study.
Human calcyon is predicted to be phosphorylated by PKC, although direct evidence has not been provided (2). We found that rat calcyon contains eight putative phosphorylation sites, but the Ser-169 residue is a unique site that can be phosphorylated by PKC. Indeed, the phospho-deficient mutant S169A largely failed to be phosphorylated by the PKC activator PMA (Fig. 4B). Interestingly, the D 1 DR-specific agonist SKF-81297 also increased the phosphorylation levels of wild-type calcyon but not those of the S169A mutant, indicating that the D 1 DR signaling pathway may activate PKC either directly or indirectly to phosphorylate calcyon.
PKC-mediated phosphorylation of calcyon does affect its binding to PSD-95. As the phosphorylation level of calcyon increases, the binding to PSD-95 increases. Because PSD-95 is known to bind D 1 DR, the phosphorylation of calcyon by PKC possibly enhances the formation of the ternary complex of calcyon⅐PSD-95⅐D 1 DR. What is the consequence of forming this ternary complex? We showed that phosphorylation of calcyon increased the internalization of D 1 DR from the cell surface. Thus, we could speculate about the existence a possible feedback loop during D 1 DR signaling. D 1 DR is activated by its agonist followed by signaling to its downstream effectors, which activates PKC that subsequently phosphorylates calcyon. The phosphorylated calcyon binds more strongly to PSD-95 and is recruited to the cell surface either by its binding to PSD-95 or by other unknown mechanisms and forms a ternary complex with PSD-95 and D 1 DR, which consequently induces the internalization of D 1 DR from the cell surface (supplemental Fig. 6). Our data imply that the formation of the calcyon⅐PSD-95⅐D 1 DR complex in dendritic spines would indirectly inhibit D 1 DR-mediated signaling by "physically" reducing the surface levels of D 1 DR and thus may provide a novel target for D 1 DRrelated neuropsychiatric diseases such as schizophrenia and attention deficit hyperactivity disorder. Whether the phosphorylation-dependent formation of a ternary complex among calcyon⅐PSD-95⅐D 1 DR directly affects D 1 DR-mediated signaling and plays a role in linking dopaminergic and glutamatergic signaling in the brain would be of great interest but certainly requires further investigation.